On the treatment of diabetes mellitus with glucagon-like peptide-1. (Q54106557)

24 May 2018

review article

1 reference

title

On the treatment of diabetes mellitus with glucagon-like peptide-1. (English)

1 reference

24 May 2018

author

Jens Juul Holst

1

1 reference

24 May 2018

author name string

Deacon C

2

1 reference

24 May 2018

Toft-Nielsen MB

3

1 reference

24 May 2018

Bjerre-Knudsen L

4

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 December 1998

1 reference

24 May 2018

Annals of the New York Academy of Sciences

published in

1 reference

24 May 2018

volume

865

1 reference

24 May 2018

page(s)

336-343

1 reference

24 May 2018

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB11193.X

10.1111/J.1749-6632.1998.TB11193.X

21 January 2018

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018